Alzheimer’s Study Finds a Target in a Stress Neurotransmitter

Alzheimer’s Study Finds a Target in a Stress Neurotransmitter
University of California researchers recently showed that the targeting of a neurotransmitter involved in stress responses significantly reduced cellular and tissue damage while preventing the onset of cognitive impairment in a transgenic mice model of Alzheimer’s disease. The study, entitled “Corticotropin-releasing factor receptor-1 antagonism mitigates beta amyloid pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease,” was published online in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. Previous research has implicated stress signaling pathways and corticotropin-releasing factor (CRF) in the pathogenesis of Alzheimer’s disease (AD). It has also been demonstrated that CRF is dysregulated in AD, leading to molecular changes in tau protein and higher production of amyloid-beta protein, forming plaques responsible for impaired cognition and progressive neurodegeneration. Furthermore, previous work has shown that CRF and its receptors are involved in another important process in AD, tau phosphorylation, confirming its mechanistic implication in pathogenicity. Despite these findings, the molecules that target CRF pathways have not been fully explored or tested for their long-term efficacy and safety in animal models. In this study, researchers used an established mouse model to explore the potential of type-1 corticotropin-releasing factor receptor (CRFR1) as a therapeutic target in the treatment of AD, using R121919, a CRF-antagonist (blocking the rec
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *